Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactobacillus + prednisone + sulfasalazine
- Development stage
- Unknown
- Lead developer
- Wanze Shuangqi Pharmaceutical
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Antibody-Based Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a combination therapy consisting of bifidobacterium and lactobacillus (probiotic bacteria), prednisone (a synthetic glucocorticoid corticosteroid), and sulfasalazine (a disease-modifying antirheumatic drug, DMARD). The combination is used in the management of inflammatory diseases such as Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Probiotics like bifidobacterium and lactobacillus help restore gut microbiota balance, enhance intestinal barrier function, and may increase the metabolism of sulfasalazine to its active anti-inflammatory components. Prednisone acts as an immunosuppressant by binding to glucocorticoid receptors to reduce inflammation. Sulfasalazine is metabolized in the colon by bacterial enzymes into 5-aminosalicylic acid (anti-inflammatory) and sulfapyridine (antibacterial). This multi-modal approach aims to improve clinical outcomes by targeting inflammation through different mechanisms[1][2][3][8].
02
Targets
GR (Glucocorticoid receptor)AzR (Bacterial azoreductase)COX
Beyond the preview
Go deeper on bifidobacterium lactobacillus + prednisone + sulfasalazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactobacillus + prednisone + sulfasalazine.